Over the past 30 years, 18,000 clinical trials that have been registered in Australia, with the sector contributing $1.4 billion to Australia’s economy annually. Trials are a critical aspect of evidence-based medicine, and are essential for testing how new treatments, tests and vaccines will work. In New Zealand they contribute $146 million to the New Zealand economy.
Australia and New Zealand have established themselves as ideal locations to host clinical trials due to their diverse participant populations, sophisticated healthcare and research environments as well as government backed support. Both countries have adopted the International Council for Harmonisation (ICH) Guideline for Good Clinical Practice (GCP) to ensure all trials collect high quality and credible data that is internationally recognised.
To capitalise on this unique position and growth, a coordinated multi-site clinical research operation was missing.
Now, three of the largest clinical trial organisations across Australia and New Zealand have united to form Momentum Clinical Research – an end-to-end clinical research network with sites that have been operating for over 20 years. Combined, they have 13 site locations across the Trans-Tasman and are set to open more locations to allow more studies to take place and enable everyday people to access new and emerging therapies.
In February 2024, New Zealand’s renowned P3 Research joined forces with Australia’s AusTrials and Holdsworth House to form Momentum Clinical Research. The combined entity can now provide sponsors a single point of contact for their current 13 sites across the two countries,
Momentum Clinical Research aims to provide quick responses to feasibility requests, faster study starts and accelerated recruitment – all leading to the delivery of high-quality results for Phase 1b-IV clinical trials. Momentum Clinical Research has become the only Trans-Tasman network of clinical trial sites.
Australian Health Journal spoke with Aus Trials Research Director, Dr Munro Neville, on the Australian clinical trial landscape more broadly and reasons for creating a Trans-Tasman clinical research organisation.
Further growth in the industry is expected, with the Australian Government having pledged $750 million to increase clinical trial activity between 2022-2032. Similarly, the New Zealand Government has invested $98 million into health research funding from 2017-2027 to facilitate the conduct of clinical trials.
You Might also like
-
From Canadian dental graduate to Australian orthodontic practice
Dr Helen Moon is a Specialist Orthodontist dedicated to delivering evidence-based, patient-centred orthodontic care. She graduated from the University of Queensland with a Bachelor of Dental Science (Honours) and began her career as a general dentist, gaining valuable experience over 2.5 years in comprehensive dental practice. This foundation provided her with a broad understanding of oral health before she pursued advanced specialist training in orthodontics.
-
Navigating the health system for mental health support
Senior professionals and middle managers are experiencing increased burnout and stress, leading to higher alcohol consumption, and there is a need for better support and resources for mental health and addiction treatment in Australia, according to Ruth Limkin, Founder of The Banyans and Chief Development Officer at parent Sana Health Group.
-
Allied Health Funding Government New Content Pharmacist Physiotherapy Students and Interns Workforce growth
Cost of living relief for students training in national skills shortage fields
The Australian Government is expanding the Commonwealth Prac Payment to eligible students in 10 additional frontline allied health disciplines, providing financial support during mandatory university placements.
From 1 July 2027, eligible students studying audiology, pharmacy, radiography, clinical psychology, physiotherapy, rehabilitation therapies, occupational therapy, podiatry, speech pathology and paramedicine will be able to access the payment.